Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts have diverse views on bluebird bio (NASDAQ:BLUE), with recent ratings ranging from indifferent to somewhat bearish. The average 12-month price target is now $2.92, down from $3.10. Analysts from RBC Capital, Wells Fargo, Wedbush, and HSBC have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. bluebird bio's financials show significant revenue growth but challenges in net margin, ROE, ROA, and debt management.
March 27, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed views on bluebird bio, with a downward adjustment in the average price target to $2.92. The company shows significant revenue growth but faces challenges in profitability and debt management.
The mixed analyst ratings and the slight decrease in the average price target suggest uncertainty about bluebird bio's future stock performance. While the significant revenue growth is a positive sign, the challenges in profitability and debt management could offset potential gains, leading to a neutral short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100